FLT3 and acute myeloid leukemia: On the other hand, the differences between control-siRNA and FLT3-siRNA or DNMT3A-siRNA carrier treatment were not significant, indicating that normal PBMC are not specifically sensitive to FLT3 or DNMT3A knockdown in contrast to AML blasts (Additional file 1: Figure S5 G).